Abstract. The combined use of anti-angiogenic therapy (AT) and radioimmunotherapy (RIT) may improve the therapeutic outcome in patients with cancer lesions. This hypothesis is based on the ability of AT to suppress tumour endothelial compartments and the direct action of RIT against tumour cells. We previously confirmed this hypothesis in an established subcutaneous xenograft model of colon cancer. The purpose of the current investigation was to determine the benefit of this combination within a liver metastasis model, which mimics treatment of minimal disease in an adjuvant setting. Liver metastases were established in nude mice by intrasplenic inoculation of LS180 colon cancer cells; following such inoculation, metastases of <1 mm in diameter can be observed at 1 week and these lesions can attain a size of several millimetres at 2 weeks. Daily AT with 2-methoxyoestradiol (2-ME), 75 mg/kg, was initiated at 1 week. RIT with 7 MBq of 131 I-A7, an IgG1 anti-colorectal monoclonal antibody, was conducted at 2 weeks. RIT employing an irrelevant IgG1, 131 I-HPMS-1, was implemented for comparison. The weight of liver metastases was measured 4 weeks after cell inoculation. The effect of AT on 131 I-A7 accumulation in metastases was also observed. Toxicity of treatment was monitored by blood cell counts. Monotherapy with 2-ME AT or 131 I-A7 RIT significantly suppressed metastasis growth (P<0.0001): metastasis weight was 5.96±0.87 g in non-treated controls, 2.67±1.89 g in cases receiving AT and 0.85±0.68 g in those receiving 131 I-A7 RIT. Combination of AT and 131 I-A7 RIT more effectively suppressed the growth to 0.28±0.32 g (P<0.05 vs RIT alone). The effect of 131 I-HPMS-1 RIT, which suppressed metastasis growth to 2.25±0.88 g, was significant in comparison with the control (P<0.0001); however, the combination of AT and 131 I-HPMS-1 RIT (which suppressed growth to 1.41±0.68 g) was far less effective than the combination of AT and 131 I-A7 RIT. AT did not decrease 131 I-A7 accumulation in metastases. AT did not affect RIT myelotoxicity. The results of this study demonstrating the combined effects of AT and 131 I-A7 RIT in a small metastasis model indicate that such combination therapy may be suitable for the treatment of minimal disease.
Introduction
Radioimmunotherapy (RIT) employing radiolabelled monoclonal antibodies (MAb) against tumours has been extensively tested for two decades. However, in most cases the results have demonstrated limited success in bulky disease [1] . On the other hand, a number of reports have suggested a role for RIT as an adjuvant treatment of cancer [2, 3, 4, 5, 6, 7, 8] . Indeed, prolonged survival with RIT has been documented in patients presenting with minimal residual disease of ovarian cancer [9] .
Neovascularisation is a prerequisite for the growth of solid tumours [10] . Tumour cells produce angiogenic factors, such as vascular endothelial growth factor (VEGF), which induce neovascularisation to support their own growth [10] ; therefore, anti-angiogenic therapy (AT) employing agents that suppress endothelial cell growth has been investigated. Moreover, clinical trials involving a number of angiogenesis inhibitors are underway. AT affords several advantages over conventional chemotherapy [10] . Firstly, AT does not generally cause bone marrow suppression or gastrointestinal symptoms. Secondly, drug resistance most likely is not a significant problem. However, AT is inhibitory or cytostatic only, which may maintain lesions at a limited size, a situation referred to as tumour dormancy. Therefore, combination with cytotoxic treatment is required for the extermination of tumour cells.
We hypothesise that combined use of anti-angiogenic therapy (AT) and radioimmunotherapy (RIT) may improve the therapeutic outcome in patients with cancer lesions [11, 12] . This hypothesis is based on the ability of AT to suppress tumour endothelial compartments and the direct action of RIT against tumour cells. Additionally, this combination may not increase bone marrow toxicity, which is the major determinant of the maximal tolerated dose of RIT. We previously demonstrated that the combination of an anti-angiogenic agent, 2-methoxyoestradiol (2-ME), which is an endogenous oestrogen metabolite [13, 14, 15, 16] , with 131 I-MAb RIT enhanced the suppression of established subcutaneous xenografts of LS180 human colon cancer cells in nude mice, in which anti-angiogenic properties of 2-ME have been proved by immunohistochemical analysis [11] . The present investigation was concerned with determination of the efficacy of RIT with 131 I-MAb in a mouse model bearing liver metastases of LS180 cells, which mimics treatment of minimal disease or adjuvant settings.
Materials and methods
Monoclonal antibody. A7, an IgG1 murine MAb with κ light chain, was used in this investigation [17] . It was purified from ascites of hybridoma-bearing mice by Protein A Sepharose column (Bio-Rad, Richmond, Calif.) chromatography. A7 MAb recognises a 45-kDa surface glycoprotein of human colonic carcinomas. An additional IgG1 recognising placental alkaline phosphatase, HPMS-1, was utilised as a class-matched irrelevant control MAb [18] . A7 was radiolabelled with iodine-131 or iodine-125 by the chloramine-T method. HPMS-1 was labelled with 131 I. MAbs were subsequently purified on a PD10 column (Pharmacia LKB Biotechnology, Uppsala, Sweden). The specific activities of purified 131 I-A7 and 125 I-A7 were 109-112 MBq/mg and 97 MBq/mg, respectively. Immunoreactivities of purified 131 I-A7 and 125 I-A7 determined under conditions of antigen excess with an LS180 human colon cancer cell line were 72%-73% and 76%, respectively. The specific activity of 131 I-HPMS-1 was 165 MBq/mg. Antibodies were sterilised by filtration (Millex-GV, 0.22 mm; Millipore, Bedford, Mass.) prior to further experiments. Liver metastasis model. Animal studies were performed in compliance with the regulations of our institution. Additionally, principles of laboratory animal care (NIH publication No. 86-23, revised 1985) were followed. LS180 cells were grown in DMEM medium (Nissui Seiyaku, Tokyo, Japan), harvested with 0.1% trypsin, washed and subsequently suspended in PBS at 2×10 7 /ml. A liver metastasis model was established in Balb/c nu/nu mice (female, 20 g; NINOX Labo Supply Inc., Ishikawa, Japan) [7, 8, 19] . Briefly, 0.1 ml of the cell suspension was injected into the spleen under inhalation anaesthesia with diethyl ether. The spleen was removed 2 min later. In this model, metastatic nodules of less than 1 mm in diameter are evident 1 week after cell inoculation [19] . At 2 weeks, many metastases attain a size of several millimetres; moreover, these metastases often fuse with one another.
Biodistribution of A7. Accumulation of 125 I-A7 in liver metastases was examined. Mice were intravenously injected with 111 kBq (3 µCi) of 125 I-A7 2 weeks after inoculation of tumour cells. The animals were sacrificed 2 (n=10) and 6 days (n=8) later. Organs were excised and weighed; subsequently, radioactivity of the tissues was measured with a well-type gamma counter. To determine 125 I-A7 accumulation in metastases, all visible nodules were separated from the liver. Total weight and radioactivity of nodules were then measured. Accumulation of the irrelevant MAb, 131 I-HMPS-1, was also assessed (n=4). Distribution of MAbs was expressed as the percentage of the injected dose per gram tissue (%ID/g).
In order to evaluate the effect of 2-ME administration on 125 I-A7 accumulation in metastases, a dose of 75 mg/kg of 2-ME (Sigma, St. Louis, Mo.) suspended in 0.1 ml of 0.5% carboxymethylcellulose (Wako, Osaka, Japan) was administered orally 1 week after the cell inoculation and daily thereafter. 125 I-A7 was injected 2 weeks after the cell inoculation, and its biodistribution was assessed 2 days later (n=5). The results were compared with those obtained from non-treated mice. 2-ME dosage was determined as previously described [13] .
Radioimmunotherapy and anti-angiogenic therapy. The therapeutic experiment consisted of six groups: non-treated mice (n=6), mice receiving AT with a daily oral dose of 75 mg/kg of 2-ME (n=8), mice undergoing specific RIT with 7 MBq (190 µCi) of 131 I-A7 (n=8), mice receiving both 131 I-A7 RIT and AT (n=8), mice undergoing non-specific RIT with 7 MBq of the irrelevant 131 I-HPMS-1 (n=6) and mice receiving both 131 I-HPMS-1 RIT and AT (n=6). To mimic the theoretical situation in which RIT would be performed during AT, AT was initiated 1 week following cell inoculation; RIT was performed at 2 weeks. 131 I-A7 dosage was determined based on a preliminary study involving 9 MBq (242 µCi) of 131 I-A7 administration in this liver metastasis model, in which half of the mice died due to radiation toxicity. The animals were sacrificed 4 weeks following the cell inoculation. Therapeutic effect was assessed by total weight of metastases. Results were analysed by one-way analysis of variance (ANOVA) with Fisher's protected least significant difference (PLSD). The level of significance was set at 5%.
To ascertain the bone marrow toxicity of treatment, a blood sample (5 µl) was obtained from a tail vein of each mouse. Samples from five mice selected at random within a single group were pooled and diluted 1:20 in 3% acetic acid for white blood cell (WBC) counts and 1:100 in 1% ammonium oxalate for platelet counts [12] .
Results
125 I-A7 accumulated almost exclusively in the LS180 liver metastases, demonstrating activity of 33.1%± 19.8%ID/g at 2 days and 6.8%±6.7%ID/g at 6 days ( Fig. 1) . Accumulation of the irrelevant MAb, HMPS-1, in metastases was only 6.6%±4.2%ID/g at 2 days; accumulation into normal organs was higher than that of A7 (Fig. 2) . Consequently, target-to-non-target ratios were approximately 7-10 times higher with 125 I-A7 (Table 1) . AT with 2-ME did not alter 125 I-A7 accumulation in metastases or normal tissues (Fig. 3) . In Fig. 4 , 125 I-A7 accumulation in liver metastases is plotted against total burden of metastases, which demonstrates the inverse correlation between A7 accumulation and metastatic burden in both non-treated and 2-ME-treated mice. No apparent difference in 125 I-A7 accumulation was observed between the two groups with regard to total weight of metastasis.
Metastases occupied most of the liver in non-treated control mice 4 weeks following intrasplenic inoculation of LS180 cancer cells (Table 2) . One mouse in the control group died due to metastases on day 26. Weight of metastases in the five surviving animals was 5.96±0.87 g on day 28. Ascites due to metastases was observed in all control mice. 2-ME AT inhibited the growth of metastases by approximately 50% as compared with the control group. However, half of the animals in the AT group displayed ascites as a result of metastases at 4 weeks. Nonspecific RIT with 131 I-HPMS-1 induced slight growth suppression; however, the effect was less significant than that achieved by specific RIT with 131 I-A7. Moreover, two mice in the non-specific RIT group died on day 25, which was probably attributable to non-specific radiation as well as metastases (Fig. 3, Table 1 ). Three of the four surviving mice in this group exhibited ascites. Combination of AT and specific RIT suppressed the growth of RIT with 131 I-A7 caused depression in WBC and platelet counts (Fig. 5) . AT involving daily administration of 2-ME did not induce appreciable myelotoxicity. In addition, combination of AT with RIT apparently did not enhance the toxicity of 131 I-A7 RIT.
Discussion
The effects of 2-methoxyoestradiol, 2-ME, on cellular proliferation have been attributed to binding to tubulin, which results in inhibition of tubulin polymerisation or formation of polymer with altered stability [13, 15, 16, 20, 21] . Previous studies have demonstrated the inhibition of angiogenic factors such as VEGF and basic fibroblast growth factor (bFGF) [13] . In addition, 2-ME directly induces apoptotic death of cancer cells [14] . We have previously shown a synergistic relationship between RIT and AT in the treatment of relatively large subcutaneous colon cancer xenografts [11, 12] , in which the anti-angiogenic and direct antitumourigenic effects of 2-ME were demonstrated using LS180 colon cancer cells [11] . Furthermore, we also observed that RIT with 131 I-A7 itself reduced microvessel numbers in xenografts, which was probably attributable to β-radiation absorption by the vascular compartment [12] .
These facts indicate that the superior antitumour effects of the combination regimen in a metastasis model were produced jointly by the anti-angiogenic and direct antitumourigenic effects of 2-ME and by the administration of β-irradiation with RIT to both the tumour cell and the vascular components. Daily treatment with 2-ME produced no adverse effects on A7 accumulation in metastatic lesions. On the other hand, in the previous study, 2-ME treatment affected A7 accumulation in subcutaneous xenografts [11] . These results suggest that the accessibility of MAb to small lesions is less influenced by 2-ME treatment than that to well-established tumours. This observation allows flexibility with respect to the administration schedule for MAbs and anti-angiogenic agents in the treatment of minimal disease; therefore, RIT administration during induction of so-called tumour dormancy by AT could be performed without influencing the radiation dose absorbed by the tumours.
Analyses using mathematical models suggest that a substantial portion of β-energy should be deposited outside of lesions owing to the millimetre pathlength of β-particles, resulting in less favourable dosimetry for small metastatic lesions [22] . In fact, however, a number of studies have proved the effectiveness of RIT with β-emitters in micrometastatic models [2, 3, 4, 5, 6, 7, 8] . Several factors must be involved in the effectiveness of RIT in the treatment of small metastases. Firstly, MAb accumulation in tumours increases with decreasing tumour size [23, 24] , although mathematical models dealing with the effect of size on tumour curability with β-emitters have assumed independence of tumour uptake from tumour size [22] . This phenomenon is observed not only in relatively large macroscopic nodules but also in microscopic nodules. Indeed, we have previously demonstrated the size dependency of A7 MAb accumulation in the liver metastasis model of LS180 cells in the range 0.1-100 mg [19] . Secondly, improved homogeneity of MAb distribution in smaller nodules can be expected [8] . Thirdly, smaller tumours can be better perfused, and consequently better oxygenated [25] . In addition, satisfactory perfusion may allow cycling of cells, which may correlate with high radiation sensitivity [26] . Fourthly, the number of clonogenic cells that needs to be killed to attain cure is limited in small metastatic lesions [27] . These various favourable factors compensate for the loss of β energy outside metastases. An advantage of the of AT with RIT arises from the fact that AT does not generally cause bone marrow suppression or gastrointestinal symptoms, which are major complications of RIT [10] . RIT with 7 MBq 131 I-A7 caused minor depression in WBC and platelet counts during the 2 weeks after 131 I-A7 injection. Because we set the end-point of the current study at 4 weeks and RIT was initiated at 2 weeks after the cell inoculation, we could observe the RIT toxicity for 2 weeks. On the other hand, in a preliminary study involving administration of 9 MBq of 131 I-A7 in this liver metastasis model, we found that half of the mice died due to radiation toxicity and the nadir of blood cell count depression in the surviving mice occurred at around 3 weeks after administration of 131 I-A7. These findings suggest that we may not have observed the nadir in the current investigation; however, the important findings are that AT involving daily administration of 2-ME did not induce myelotoxicity. Furthermore, it did not contribute appreciably to myelotoxicity in mice treated with RIT. In addition, as a non-toxic oestrogen metabolite occurring in normal human urine, 2-ME has virtually no effect on non-proliferating cells. These facts indicate that the combined use of 2-ME and RIT is attractive in terms of both the therapeutic efficacy and the toxicity profile.
In conclusion, this study demonstrates the remarkable therapeutic efficacy of 131 I-A7 RIT in treating liver metastases of limited size. The inverse correlation observed between A7 accumulation and metastatic burden indicates that minimal disease is especially amenable to such treatment. Furthermore, RIT and AT with 2-ME were shown to have a synergistic role in the treatment of metastases. While treatment of endothelial compartments with AT may limit growth of metastases, RIT may effectively eradicate lesions of limited size on the basis of its cytotoxic effect on tumour cells. This combination regimen may be an appropriate choice for the treatment of minimal disease or in adjuvant settings following conventional therapy. To further test this hypothesis, we are currently planning to investigate the effect of this combination on the long-term survival of animals.
